Business
MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock
Financing included participation by healthcare-dedicated investors alongsideexisting shareholders CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $1.50 per share for aggregate gross proceeds of $30 mil
About this update from Maia Biotechnology, Inc.
[{"type":"image","alt":"MAIA Biotechnology, Inc.","displaySize":"","headline":null,"caption":"MAIA Biotechnology, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":114,"url":"https://media.zenfs.com/en/globenewswire.com/fbd77a311f7c68878bc3292efbebb483"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VsKDoji6rq9.7IotAdlg.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/fbd77a311f7c68878bc3292efbebb483","width":300,"height":114}},"lazy":false},{"type":"text","content":"Financing included participation by healthcare-dedicated investors alongsideexisting shareholders","length":98,"tagName":"p"},{"type":"text","content":"CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $1.50 per share for aggregate gross proceeds of $30 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 3,000,000 shares of common stock at the public offering price per share, less the underwriting discounts to cover over-allotments, if any. The offering is expected to close on March 4, 2026, subject to satisfaction of customary closing conditions.","length":828,"tagName":"p"},{"type":"text","content":"The offering was structured as a straightforward common stock only investment with no warrant coverage and was led by healthcare-dedicated investors alongside existing shareholders.","length":181,"tagName":"p"},{"type":"text","content":"Konik Capital Partners, LLC, a division of T.R. Winston & Company is acting as the sole book-running manager for the offering.","length":130,"tagName":"p"},{"type":"text","content":"MAIA intends to use the net proceeds from the offering to conduct clinical trials and for working capital and general corporate purposes.","length":137,"tagName":"p"},{"type":"text","content":"The securities described above are being offered and sold pursuant to a “shelf” registration statement on Form S-3 (File No. 333-273984), including a base prospectus, filed with ...